Development of real-time quantitative reverse transcription-PCR for Her2 detection in peripheral blood from patients with breast cancer

Clinica Chimica Acta

Volumn 384, Issue 1-2, 2007, Pages 52-56

  Savino, Maria ^a   Garrubba, Maria ^a   Parrella, Paola ^a   Baorda, Filomena ^a   Copetti, Massimiliano ^b   Murgo, Roberto ^a   Zelante, Leopoldo ^a   Carella, Massimo ^a   Valori, Vanna Maria ^a   Santini, Stefano Angelo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

Author keywords

Breast cancer; HER2; IHC; Quantitative PCR; Tumoral markers

Indexed keywords

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 34547850290     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.05.023     Document Type: Article

References (18)

1. Bundred N.J. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27 (2001) 137-142
2. Rahaman Z.U., Frye D.K., Buzdar A.U., et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15 (1997) 3171-3177
3. Abrams J., Aisner J., Cirrincione C., et al. Dose-response trial of megestrol acetatet in advanced breast cancer: cancer and leucemia group B phase III study. J Clin Oncol 17 (1999) 64-73
4. Mouridsen H., Gershanovic M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001) 2596-2606
5. Ravdin P.M., Green S., Door T.M., et al. Prognostic significance of estrogen receptor levels in estrogen receptor positive patients with metatstatic breast cancer treated with tamoxifen:results of a prospective Southwest Oncology Group Study. J Clin Oncol 10 (1992) 1284-1291
6. Ullrich A., and Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 61 (1990) 203-212
7. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
8. Paik S., Hazan R., Fisher E.R., et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8 (1990) 103-112
9. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of transtuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
10. Burstein H.J., Harris L.N., Marcom K., et al. Tastuzumab and vinorelbine as first-line theraphy of HER-2 overexpressing metatstatic breast cancer: multi-center phase II trail with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21 (2003) 2889-2895
11. Press M.F., Slamon D.J., Flom K.J., et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20 (2002) 3095-3105
12. Leonard D.S., Hill A.D., Kelly L., et al. Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer. Br J Surg 89 (2002) 262-271
13. 0 breast cancer: a nationwide population-based study. Clin Cancer Res 9 (2003) 923-930
14. Pauletti G., Dandekar S., Rong H., et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18 (2000) 3651-3664
15. Nahta R., and Esteva F.J. HER-2-targeted therapy. Clin Cancer Res 9 (2003) 5078-5084
16. Ellis C.M., Dyson M.J., Stephenson T.J., and Maltby E.L. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol 58 (2005) 710-714
17. Persons D.L., Bui M.M., Lowery M.C., et al. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci 30 (2000) 41-48
18. Smith B.M., Slade M.J., English J., et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 18 (2000) 1432-1439